Immunotherapy

DBCAT005063Pharmacologic class

Manipulation of the host's immune system in treatment of disease. It includes both active and passive immunization as well as immunosuppressive therapy to prevent graft rejection. A DrugBank category of 104 drugs. 102 of them are approved.

Drugs: Aldesleukin
Alemtuzumab
Anakinra
Antilymphocyte immunoglobulin (horse)
Antithymocyte immunoglobulin (rabbit)
Apremilast
Atezolizumab
Avelumab
Axicabtagene ciloleucel
Azathioprine
BCG vaccine
Belantamab mafodotin
Belinostat
Bevacizumab
Blinatumomab
Brentuximab vedotin
Brexucabtagene autoleucel
Catumaxomab
Cemiplimab
Certolizumab pegol
Cetuximab
Daclizumab
Daratumumab
Denileukin diftitox
Denosumab
and 79 more with a free account

What you can answer from here — as of July 19, 2019

104DrugsEach linked to its full drug card

115Drug targetsEvery drug–target pair in the class, with bond type

6,035Marketed productsAcross the regions we cover, with dosage forms and routes

23Routes of administrationHow the drugs in this class are given

1SubcategoryNarrower classes within this one

Which targets do Immunotherapy share, and which companies have late-stage candidates in this class?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account